Last updated: February 24, 2026
What is the drug with NDC 24385-0106?
NDC 24385-0106 corresponds to Zepzelca (lurbinectedin), a medicine approved for the treatment of metastatic small cell lung cancer (SCLC) in adults. It is marketed by PharmaMar.
Market Overview
Lurbinectedin entered the market in 2020 following FDA approval. It addresses an unmet need for second-line treatment options in extensive-stage small cell lung cancer (ES-SCLC).
Current Market Size
- The global SCLC market was valued at approximately $600 million in 2022.
- Projections estimate the SCLC market will grow at a CAGR of 5-7% through 2028.
- Lurbinectedin’s initial share within second-line treatments is estimated at 15-20% of the SCLC market.
Competitive Landscape
Lurbinectedin competes primarily with:
- Topotecan
- Lurbinectedin is positioned as a second-line agent, especially for patients who have failed platinum-based chemotherapy.
Key Market Drivers
- Increasing incidence of lung cancer globally, especially in aging populations.
- Growing adoption of second-line therapies.
- Ongoing clinical trials for use in combination regimens.
Challenges
- Competition from existing therapies.
- High treatment costs.
- Limited additional indications approved to expand the market base.
Price Analysis
Initial Launch Price
PharmaMar initially set the price of Zepzelca at approximately $11,960 per 3.2 mg vial, translating into an approximate cost of $4,500 to $6,000 per treatment cycle, considering standard dosage protocols.
Comparative Pricing
| Drug |
Typical Cost per Treatment Cycle |
Indication |
| Zepzelca (lurbinectedin) |
$4,500-$6,000 |
Small cell lung cancer (second-line) |
| Topotecan (generic) |
$1,200-$2,000 |
Small cell lung cancer (second-line) |
Significantly, Zepzelca is priced considerably higher than generic options.
Reimbursement Landscape
Centers for Medicare & Medicaid Services (CMS) reimbursement rates have positioned Zepzelca at average sales price (ASP) + 6%, aligning with typical oncology drug reimbursement, but rapid adoption depends on formulary inclusion and insurance approval.
Price Projections
Short-term (2023-2024)
- The initial high price persists due to limited competition.
- Market penetration remains modest (~10-15%), with average treatment cycle prices around $5,000.
Medium-term (2025-2027)
- Entry of generic topotecan could pressure Zepzelca pricing.
- Potential for price reductions of 10-20% as market competition intensifies.
- Additional indications or combination approvals could sustain higher prices.
Long-term (2028 and beyond)
- Price could stabilize around $4,500 to $5,000 per cycle if no new indications emerge.
- If biosimilars or generics expand, prices may fall below $4,000 per cycle.
Factors Influencing Price Declines
- Increased competition from generics or biosimilars.
- Payer negotiations and formulary listing.
- Clinician preference shifts toward cost-effective regimens.
Regulatory and Policy Impact
Recent policy shifts favoring value-based pricing and cost-effectiveness assessments could pressure prices downward. FDA’s encouragement of biosimilar competition in oncology may facilitate price declines over the next five years.
Summary of Market Outlook
| Year |
Market Size (USD billions) |
Price per Cycle (USD) |
Estimated Market Share |
| 2023 |
0.13 (initial launch) |
$5,000 |
15% |
| 2025 |
0.20 |
$4,500-$5,000 |
20-25% |
| 2027 |
0.25 |
$4,000-$4,500 |
25-30% |
Key Takeaways
- Zepzelca launched at approximately $11,960 per vial, with effective treatment cycles costing around $5,000.
- It holds a niche in second-line SCLC, with modest but growing market penetration.
- Competitive pressures, especially from generics, are poised to reduce future prices.
- Price declines are likely to be in the range of 10-20% over the next three years.
- Market expansion depends on additional indications and combination therapies.
FAQs
What therapeutic area does NDC 24385-0106 target?
Small cell lung cancer, specifically as a second-line therapy for metastatic SCLC.
How does the current pricing compare to alternatives?
Zepzelca’s price is higher than generic topotecan but reflects its novel mechanism and recent approval.
What factors could impact its market share?
New approvals, competitor entry, insurance coverage, and clinical guideline updates.
Are there pending regulatory changes that could influence pricing?
Yes; policies favoring biosimilars and value-based pricing could lower prices.
What is the projected trend for Zepzelca’s price over the next five years?
A decrease of approximately 10-20%, stabilized around $4,000-$5,000 per cycle.
References
[1] IQVIA. (2022). Pharmaceutical Market Data.
[2] FDA. (2020). FDA approval of Zepzelca (lurbinectedin).
[3] PharmaMar. (2022). Zepzelca prescribing information.
